Leveraging Mobile and Wearable Technology for Outcomes Research in Depression
July 22, 2025
As mobile and wearable technologies become increasingly integrated into daily life, their applications have expanded far beyond convenience and lifestyle. In the field of outcomes research — particularly within mental health — these technologies are opening new frontiers for understanding and monitoring clinical endpoints. A notable case is depression, where continuous digital monitoring can provide rich insights into both the course of illness and treatment impact.
This post draws on our findings from a recent systematic review and poster presentation to examine how mobile and wearable tools are currently deployed in depression monitoring and how this aligns with broader outcomes research goals.
Digital monitoring as a tool for mental health outcomes
Over the past five to six years, depression has seen a marked rise across youth and adult populations globally, underscoring the need for scalable and effective monitoring strategies. In parallel, smartphones and wearables have become ubiquitous, capable of capturing passive, longitudinal health data. These digital tools offer unprecedented potential for outcomes research by providing real-time behavioral and physiological markers relevant to depression.
To map the current landscape, we conducted a comprehensive literature review focused on how smartphones and wearables are used to monitor depression in research contexts. This synthesis aimed to highlight prevailing methods, feature usage, and the extent to which demographic variability is accounted for — critical considerations in health outcomes analysis.
Key findings from the literature
We reviewed 140 studies and identified 22 that met our inclusion criteria. The following themes emerged:
Study characteristics
- Recency: Most studies were published in 2024, reflecting the field’s rapid acceleration.
- Geography: The U.S. and Pakistan emerged as leading contributors.
- Sample Size: Studies included an average of 465 participants, suggesting moderately powered observational designs.
Demographic reporting
- Gender and age: Captured in 20 of the 22 studies.
- Ethnicity: Reported in just 9 studies.
- Education and marital status: Only 4 studies reported these variables — yet both are key social determinants of health and influence depression outcomes.
Monitoring technologies and features
- Smartphones were used in 20 of the 22 studies, highlighting their dominance.
- Key features monitored included:
- Mood tracking: 20 studies
- Movement (accelerometer data): 10 studies
- Heart Rate Variability (HRV): 5 studies
- Word usage tracking: 4 studies
- Sleep patterns: 2 studies
Clinical assessment tools
Self-reported clinical scales were commonly used as outcome anchors:
- PHQ-9 (Patient Health Questionnaire-9): 6 studies
- GAD-7 (Generalized Anxiety Disorder-7): 7 studies
(See our original poster for a visual breakdown of these features and tools.)
Implications for outcomes research
From an outcomes research perspective, these technologies offer compelling advantages:
- Continuous and passive monitoring: Enables longitudinal capture of clinically relevant endpoints like mood, behavior, and sleep — reducing bias from intermittent self-reporting.
- Scalability and reach: Mobile-based data collection can extend to underserved and geographically dispersed populations, improving study generalizability.
- Early signal detection: Passive data streams can flag deterioration or improvement earlier than clinical visits alone, offering potential for timely interventions.
However, a consistent limitation observed in the literature is the underreporting of demographic variables — especially education and marital status. This omission constrains subgroup analysis and limits insights into how different populations experience depression and respond to interventions. In outcomes research, such data are essential for contextualizing and stratifying results across socioeconomic or cultural dimensions.
The path forward
As wearable and mobile sensors become more refined, their integration into real-world data frameworks will likely become standard practice in outcomes research. But to truly capitalize on this potential, researchers must enhance demographic reporting and examine interactions between digital phenotypes and traditional health indicators across diverse populations.
These tools not only offer more granular tracking of mental health status — they also help researchers and health systems better understand the dynamics of treatment effectiveness, burden of illness, and quality of life over time.
Interested in learning more?
This blog summarizes findings from the poster presentation, “Exploring Mobile and Wearable Technology for Early Depression Detection and Monitoring,” presented by Lyuboslav Ivanov and Manuel Cossio at Cytel and Universitat de Barcelona.
Contact Us!Subscribe to our newsletter
Manuel Cossio
Director, Innovation and Strategic Consulting
Manuel Cossio is Director, Innovation and Strategic Consulting at Cytel. Manuel is an AI engineer with over a decade of experience in healthcare AI research and development. He currently leads the creation of generative AI solutions aimed at optimizing clinical trials, focusing on hierarchical multi-agent systems with multistage data governance and human-in-the-loop dynamic behavior control.
Manuel has an extensive research background with publications in computer vision, natural language processing, and genetic data analysis. He is a registered Key Opinion Leader at the Digital Medicine Society, a member of the ISPOR Community of Interest in AI, a Generative AI evaluator for the EU Commission, and an AI researcher at UB-UPC- Barcelona Supercomputing Center.
He holds an M.Sc. in Translational Medicine from Universitat de Barcelona, a Master of Engineering in AI from Universitat Politècnica de Catalunya, and a M.Sc. in Neuroscience from Universitat Autònoma de Barcelona.
Read full employee bioClaim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.